PR Newswire
11 Jun 2022, 05:15 GMT+10
PROVIDENCE, R.I., June 11, 2022 /PRNewswire/ -- EpiVax, Inc. ("EpiVax") announces that it has developed VennVax, a smallpox vaccine candidate that is predicted to be highly effective against monkeypox. The development of this vaccine was funded by the National Institutes of Health (SBIR grant #R43AI058376). The company is looking for a strategic partner with funding and experience in advanced preclinical development and clinical trials to move this "Epitope-Driven Vaccine" into clinical trials. Although the U.S. government has stockpiled two vaccinia virus vaccines for both smallpox and monkeypox, a next generation subunit vaccine may offer a dose-sparing strategy that increases availability of one of the vaccines and avoids safety risks of the other.
Experts in T cell biology, EpiVax scientists have been developing novel T cell epitope vaccines since the company was founded in 1998. This vaccine is named VennVax because it was developed by defining conserved elements between vaccinia (the cowpox virus) and smallpox (the disease that vaccinia vaccine protects against). These conserved elements (T cell epitopes) are also conserved in monkeypox. Initial studies in HLA transgenic mice demonstrated 100% survival rates.
EpiVax has also marked progress this year on a new vaccine for avian influenza that incorporates an immune-engineered H7N9 Hemagglutinin (HA) vaccine antigen, which increased the immunogenicity and efficacy in mouse models. Publication forthcoming in an upcoming 2022 issue of Human Vaccines & Immunotherapeutics. This follows promising results for a Q Fever T cell vaccine candidate published in Frontiers in Immunology in May 2022, in collaboration with Massachusetts General Hospital Scientists.
Dr. Lenny Moise, Director of Vaccine Research at EpiVax had this to say on the potential of T cell vaccine technology: "We are optimistic about the future for vaccines designed to exploit T cell immunity. Our T cell-directed smallpox vaccine shows it's possible to fully protect against disease without inducing an antibody response. And when antibodies are needed, whole antigens can be sculpted to trigger stronger T cell responses for increased vaccine efficacy."
EpiVax is a biotechnology company with expertise in T cell epitope prediction, immune modulation, and rapid vaccine design. EpiVax's screening toolkits for therapeutics and vaccines are employed in advancing the research of a global roster of companies.
For more information, visit www.epivax.com.
Press Contact:
Katie Porter, Business Development Manager
EpiVax
kporter@epivax.com
SOURCE EpiVax Inc.
Get a daily dose of Asia Bulletin news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Asia Bulletin.
More InformationMOSCOW, Russia: The UK newspaper, the Telegraph, has been blocked in Russia, following a request from the Russian prosecutor-general.The TASS ...
LAHORE, Pakistan - An Airbus 320 carrying 171 passengers narrowly avoided an accident at Allama Iqbal International Airport, Pakistan's second-largest ...
WASHINGTON, DC - U.S. President Joe Biden on Friday vowed to "do all in my power" to protect a woman's ...
YANGON, Myanmar - According to military-run media, a junta delegation discussed nuclear technology collaboration with a Russian state-owned atomic energy ...
DHAKA, Bangladesh - The United States Agency for International Development (USAID) is providing more than Tk2.3 crore in emergency funding ...
PHNOM PENH, Cambodia: Cambodian villagers on the Mekong River have caught a stingray fish weighing 661 pounds, which is the ...
SYDNEY, NSW, Australia - Stocks across Asia rose on Monday, in a positive start to the week.The U.S. dollar was ...
TOKYO, Japan: Amidst semiconductor shortages and COVID-19 parts supply disruptions, Toyota has reduced its July global production target by 50,000 ...
NEW YORK CITY, New York: Electric vehicle (EV) sales could reach 33 percent globally by 2028, and 54 percent by ...
BERLIN, Germany: To prevent large increases in food prices, officials from G7 countries, including Germany and the UK, will push ...
WASHINGTON D.C.: The U.S. Food and Drug Administration (FDA) is preparing to order Juul Labs to stop selling its e-cigarettes ...
WASHINGTON D.C.: As average home prices surged to a record high, reaching the $400,000 mark for the first time, and ...